120 related articles for article (PubMed ID: 8616905)
1. Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration.
Boddy AV; Yule SM; Wyllie R; Price L; Pearson AD; Idle JR
Cancer Chemother Pharmacol; 1996; 38(2):147-54. PubMed ID: 8616905
[TBL] [Abstract][Full Text] [Related]
2. Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics.
Boddy AV; English M; Pearson AD; Idle JR; Skinner R
Eur J Cancer; 1996 Jun; 32A(7):1179-84. PubMed ID: 8758250
[TBL] [Abstract][Full Text] [Related]
3. Comparison of continuous infusion and bolus administration of ifosfamide in children.
Boddy AV; Yule SM; Wyllie R; Price L; Pearson AD; Idle JR
Eur J Cancer; 1995; 31A(5):785-90. PubMed ID: 7640054
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients.
Boddy AV; Proctor M; Simmonds D; Lind MJ; Idle JR
Eur J Cancer; 1995; 31A(1):69-76. PubMed ID: 7695982
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide.
Kaijser GP; Keizer HJ; Beijnen JH; Bult A; Underberg WJ
Anticancer Res; 1996; 16(5B):3247-57. PubMed ID: 8920799
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach.
Kerbusch T; de Kraker J; Mathĵt RA; Beijnen JH
Clin Pharmacokinet; 2001; 40(8):615-25. PubMed ID: 11523727
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer.
Willits I; Price L; Parry A; Tilby MJ; Ford D; Cholerton S; Pearson AD; Boddy AV
Br J Cancer; 2005 May; 92(9):1626-35. PubMed ID: 15827549
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children.
Boddy AV; Yule SM; Wyllie R; Price L; Pearson AD; Idle JR
Cancer Res; 1993 Aug; 53(16):3758-64. PubMed ID: 8339288
[TBL] [Abstract][Full Text] [Related]
9. Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites.
Kerbusch T; Mathôt RA; Keizer HJ; Kaijser GP; Schellens JH; Beijnen JH
Drug Metab Dispos; 2001 Jul; 29(7):967-75. PubMed ID: 11408362
[TBL] [Abstract][Full Text] [Related]
10. New insights into the clinical pharmacokinetics of trofosfamide.
Brinker A; Kisro J; Letsch C; Brüggemann SK; Wagner T
Int J Clin Pharmacol Ther; 2002 Aug; 40(8):376-81. PubMed ID: 12467306
[TBL] [Abstract][Full Text] [Related]
11. The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion.
Boddy AV; Cole M; Pearson AD; Idle JR
Cancer Chemother Pharmacol; 1995; 36(1):53-60. PubMed ID: 7720176
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of ifosfamide and some metabolites in children.
Kaijser GP; De Kraker J; Bult A; Underberg WJ; Beijnen JH
Anticancer Res; 1998; 18(3B):1941-9. PubMed ID: 9677448
[TBL] [Abstract][Full Text] [Related]
13. Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms.
Calinski DM; Zhang H; Ludeman S; Dolan ME; Hollenberg PF
Drug Metab Dispos; 2015 Jul; 43(7):1084-90. PubMed ID: 25934575
[TBL] [Abstract][Full Text] [Related]
14. Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients.
Granvil CP; Ducharme J; Leyland-Jones B; Trudeau M; Wainer IW
Cancer Chemother Pharmacol; 1996; 37(5):451-6. PubMed ID: 8599868
[TBL] [Abstract][Full Text] [Related]
15. [Ifosfamide and the metabolites of side chain oxidation--excretion in urine in various pediatric therapeutic protocols].
Boos J; Welslau U; Ritter J; Blaschke G; Schellong G
Klin Padiatr; 1992; 204(4):299-305. PubMed ID: 1518269
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of trofosfamide and its dechloroethylated metabolites.
Hempel G; Krümpelmann S; May-Manke A; Hohenlöchter B; Blaschke G; Jürgens H; Boos J
Cancer Chemother Pharmacol; 1997; 40(1):45-50. PubMed ID: 9137528
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo.
Börner K; Kisro J; Brüggemann SK; Hagenah W; Peters SO; Wagner T
Drug Metab Dispos; 2000 May; 28(5):573-6. PubMed ID: 10772637
[TBL] [Abstract][Full Text] [Related]
18. Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children.
Boos J; Welslau U; Ritter J; Blaschke G; Schellong G
Cancer Chemother Pharmacol; 1991; 28(6):455-60. PubMed ID: 1934249
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients.
Kerbusch T; vanPutten JW; Groen HJ; Huitema AD; Mathĵt RA; Beijnen JH
Cancer Chemother Pharmacol; 2001 Jul; 48(1):53-61. PubMed ID: 11488525
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.
Kerbusch T; Jansen RL; Mathôt RA; Huitema AD; Jansen M; van Rijswijk RE; Beijnen JH
Clin Pharmacol Ther; 2001 Aug; 70(2):132-41. PubMed ID: 11503007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
